Skip to main content

Advertisement

SpringerLink
Log in

Idiopathic macular hole: analysis of visual outcomes and the use of indocyanine green or brilliant blue for internal limiting membrane peel

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Our aim was to analyze outcomes of idiopathic macular hole surgeries in relation to staging and the use of indocyanine green (ICG) or brilliant blue (BB) for internal limiting membrane (ILM) peel.

Methods

Baseline, surgical, and outcome data for 351 consecutive primary macular hole surgeries was prospectively collected using electronic medical record software between 2001 and 2011. The outcomes for these cases were analysed in relation to staging and the use of ICG (0.5 mg/ml) or BB for ILM peel.

Results

Mean age was 68.9 years (range 39–87) with 66.4 % females and 54.1 % right eyes. Follow-up duration was median 0.55 years. Vision was significantly improved from logMAR 0.97 (SD 0.45) (Snellen equivalent 20/185) preoperatively to 0.65 (SD 0.51) (20/90) at final follow-up. One hundred and eighteen patients had stage 2 macular holes, 185 stage 3, and 48 stage 4. Mean duration of symptoms varied with stage of hole: stage 2 0.53 years (SD 0.43), stage 3 0.79 years (SD 0.68), and stage 4 1.20 years (SD 1.26), p = 0.0002. Closure rates of the holes were significantly different, with stage 2 closing in 95.8 %, stage 3 in 73.0 %, and stage 4 in 56.3 %, p < 0.0001. At final follow-up, mean visual acuity (VA) was 0.42 (SD 0.33) (20/50) for stage 2, 0.75 (SD 0.53) (20/110) for stage 3, and 0.87 (SD 0.60) (20/145) for stage 4 holes, p < 0.0001.

Postoperative VA was 0.71 (SD 0.53) (20/100) for patients in whom ICG was used, and 0.52 (SD 0.43) (20/70) for BB, p = 0.003. The proportion of patients who achieved a closed hole was less for ICG (73.2 %) than BB (89.9 %), p = 0.0005. For those patients with stage 2 hole who achieved hole closure, mean improvement in VA was significantly better for BB (0.47, SD 0.36) than for ICG (0.30, SD 0.31), p = 0.01.

Conclusions

Macular hole stage is a useful measure to help predict the chance of postoperative hole closure and visual outcome. The relationship between duration of symptoms and increasing stage suggests macula hole patients require prompt referral for consideration of early surgery. Better visual outcomes were achieved with BB for ILM peel than with ICG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kelly NE, Wendel RT (1991) Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 109:654–659

    Article  CAS  PubMed  Google Scholar 

  2. Gass JD (2003) Idiopathic senile macular hole: its early stages and pathogenesis. 1988. Retina 23(6 Suppl):629–639

    PubMed  Google Scholar 

  3. Gass JD (1995) Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 119:752–759

    CAS  PubMed  Google Scholar 

  4. Jaycock PD, Bunce C, Xing W, Thomas D, Poon W, Gazzard G, Williamson TH, Laidlaw DA (2005) Outcomes of macular hole surgery: implications for surgical management and clinical governance. Eye 19:879–884

    Article  CAS  PubMed  Google Scholar 

  5. Da Mata AP, Burk SE, Riemann CD, Rosa RH Jr, Snyder ME, Petersen MR, Foster RE (2001) Indocyanine green-assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for macular hole repair. Ophthalmology 108:1187–1192

    Article  PubMed  Google Scholar 

  6. Da Mata AP, Burk SE, Foster RE, Riemann CD, Petersen MR, Nehemy M, Augsburger JJ (2004) Long-term follow-up of indocyanine green-assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for idiopathic macular hole repair. Ophthalmology 111:2246–2253

    Article  PubMed  Google Scholar 

  7. Dori D, Thoelen AM, Akalp F, Bernasconi PP, Messmer EP (2003) Anatomic and functional results of vitrectomy and long-term intraocular tamponade for stage 2 macular holes. Retina 23:57–63

    Article  PubMed  Google Scholar 

  8. Ezra E, Gregor ZJ (2004) Surgery for idiopathic full-thickness macular hole: two-year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Morfields Macular Hole Study Group Report no. 1. Arch Ophthalmol 122:224–236

    Article  PubMed  Google Scholar 

  9. Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, Le Gargasson JF, Mundler O, Drouet L (1995) Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 233:549–554

    Article  CAS  PubMed  Google Scholar 

  10. Korobelnik JF, Hannouche D, Belayachi N, Branger M, Guez JE, Hoang-Xuan T (1996) Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Ophthalmology 103:590–594

    Article  CAS  PubMed  Google Scholar 

  11. Minihan M, Goggin M, Cleary PE (1997) Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. Br J Ophthalmol 81:1073–1079

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Korobelnik JF, Le Gargasson JF, Gaudric A (1999) Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 106:932–938

    Article  CAS  PubMed  Google Scholar 

  13. Banker AS, Freeman WR, Azen SP, Lai MY (1999) A multicentered clinical study of serum as adjuvant therapy for surgical treatment of macular holes. Vitrectomy for Macular Hole Study Group. Arch Ophthalmol 117:1499–1502

    Article  CAS  PubMed  Google Scholar 

  14. Wachtlin J, Jandeck C, Potthöfer S, Kellner U, Foerster MH (2003) Long-term results following pars plana vitrectomy with platelet concentrate in pediatric patients with traumatic macular hole. Am J Ophthalmol 136: 197–199

    Article  PubMed  Google Scholar 

  15. Lansing MB, Glaser BM, Liss H, Hanham A, Thompson JT, Sjaarda RN, Gordon AJ (1993) The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 100:868–871

    Article  CAS  PubMed  Google Scholar 

  16. Rosa RH Jr, Glaser BM, de la Cruz Z, Green WR (1996) Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. Am J Ophthalmol 122:853–863

    PubMed  Google Scholar 

  17. Tognetto D, Grandin R, Sanguinetti G, Minutola D, Di Nicola M, Di Mascio R, Ravalico G, Macular Hole Surgery Study Group (2006) Internal limiting membrane removal during macular hole surgery: results of a multicenter retrospective study. Ophthalmology 113:1401–1410

    Article  PubMed  Google Scholar 

  18. Sheidow TG, Blinder KJ, Holekamp N, Joseph D, Shah G, Grand MG, Thomas MA, Bakal J, Sharma S (2003) Outcome results in macular hole surgery: an evaluation of internal limiting membrane peeling with and without indocyanine green. Ophthalmology 110:1697–1701

    Article  PubMed  Google Scholar 

  19. Lois N, Burr J, Norrie J, Vale L, Cook J, McDonald A, Boachie C, Ternent L, McPherson G, Full-thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS) Group (2011) Internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole: a pragmatic randomized controlled trial. Invest Ophthalmol Vis Sci 52:1586–1589

    Article  PubMed  Google Scholar 

  20. Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S (2000) Staining of internal limiting membrane in macular hole surgery. Arch Ophthalmol 118:1116–1118

    Article  CAS  PubMed  Google Scholar 

  21. Christensen UC, Krøyer K, Sander B, Larsen M, Henning V, Villumsen J, la Cour M (2009) Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol 93:1005–1015

    Article  CAS  PubMed  Google Scholar 

  22. Kwok AK, Lai TY, Man-Chan W, Woo DC (2003) Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery. Br J Ophthalmol 87:71–74

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Lee KL, Dean S, Guest S (2005) A comparison of outcomes after indocyanine green and trypan blue assisted internal limiting membrane peeling during macular hole surgery. Br J Ophthalmol 89:420–424

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Engelbrecht NE, Freeman J, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Martin DF, Sippy BD (2002) Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 133:89–94

    Article  PubMed  Google Scholar 

  25. Ho JD, Tsai RJ, Chen SN, Chen HC (2003) Cytotoxicity of indocyanine green on retinal pigment epithelium: implications for macular hole surgery. Arch Ophthalmol 121:1423–1429

    Article  CAS  PubMed  Google Scholar 

  26. Ho JD, Tsai RJ, Chen SN, Chen HC (2004) Removal of sodium from the solvent reduces retinal pigment epithelium toxicity caused by indocyanine green: implications for macular hole surgery. Br J Ophthalmol 88:556–559

    Article  PubMed Central  PubMed  Google Scholar 

  27. Ando F, Sasano K, Ohba N, Hirose H, Yasui O (2004) Anatomic and visual outcomes after indocyanine green-assisted peeling of the retinal internal limiting membrane in idiopathic macular hole surgery. Am J Ophthalmol 137:609–614

    PubMed  Google Scholar 

  28. Gass CA, Haritoglou C, Schaumberger M, Kampik A (2003) Functional outcome of macular hole surgery with and without indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 241:716–720

    Article  PubMed  Google Scholar 

  29. Weinberger AW, Kirchhof B, Mazinani BE, Schrage NF (2001) Persistent indocyanine green (ICG) fluorescence 6 weeks after intraocular ICG administration for macular hole surgery. Graefes Arch Clin Exp Ophthalmol 239:388–390

    Article  CAS  PubMed  Google Scholar 

  30. Ciardella AP, Schiff W, Barile G, Vidne O, Sparrow J, Langton K, Chang S (2003) Persistent indocyanine green fluorescence after vitrectomy for macular hole. Am J Ophthalmol 136:174–177

    Article  PubMed  Google Scholar 

  31. Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, Kampik A (2002) Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. Am J Ophthalmol 134:836–841

    Article  PubMed  Google Scholar 

  32. Horio N, Horiguchi M (2004) Effect on visual outcome after macular hole surgery when staining the internal limiting membrane with indocyanine green dye. Arch Ophthalmol 122:992–996

    Article  PubMed  Google Scholar 

  33. Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T (2006) Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 26:631–636

    Article  PubMed  Google Scholar 

  34. Enaida H, Hisatomi T, Goto Y, Hata Y, Ueno A, Miura M, Kubota T, Ishibashi T (2006) Preclinical investigation of internal limiting membrane staining and peeling using intravitreal brilliant blue G. Retina 26:623–630

    Article  PubMed  Google Scholar 

  35. Ueno A, Hisatomi T, Enaida H, Kagimoto T, Mochizuki Y, Goto Y, Kubota T, Hata Y, Ishibashi T (2007) Biocompatibility of brilliant blue G in a rat model of subretinal injection. Retina 27:499–504

    Article  PubMed  Google Scholar 

  36. Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C (2008) An in vivo evaluation of Brilliant Blue G in animals and humans. Br J Ophthalmol 92:1142–1147

    Article  CAS  PubMed  Google Scholar 

  37. Schumann RG, Remy M, Grueterich M, Gandorfer A, Haritoglou C (2008) How it appears: electron microscopic evaluation of internal limiting membrane specimens obtained during brilliant blue G assisted macular hole surgery. Br J Ophthalmol 92:330–331

    Article  PubMed  Google Scholar 

  38. Schumann RG, Gandorfer A, Priglinger SG, Kampik A, Haritoglou C (2009) Vital dyes for macular surgery: a comparative electron microscopy study of the internal limiting membrane. Retina 29:669–676

    Article  PubMed  Google Scholar 

  39. Baba T, Hagiwara A, Sato E, Arai M, Oshitari T, Yamamoto S (2012) Comparison of vitrectomy with brilliant blue G or indocyanine green on retinal microstructure and function of eyes with macular hole. Ophthalmology 119:2609–2615

    Article  PubMed  Google Scholar 

  40. Williamson TH (2008) Vitreoretinal surgery. Springer, Berlin Heidelberg New York

    Google Scholar 

  41. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391

    CAS  PubMed  Google Scholar 

  42. Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk I, Olk RJ (1994) Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol 112:359–364

    Article  CAS  PubMed  Google Scholar 

  43. Freeman WR, Azen SP, Kim JW, El-Haig W, Mishell DR III, Bailey I (1997) Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group. Arch Ophthalmol 115:11–21

    Article  CAS  PubMed  Google Scholar 

  44. Leonard RE 2nd, Smiddy WE, Flynn HW Jr, Feuer W (1997) Long-term visual outcomes in patients with successful macular hole surgery. Ophthalmology 104:1648–1652

    Article  PubMed  Google Scholar 

  45. Stec LA, Ross RD, Williams GA, Trese MT, Margherio RR, Cox MS Jr (2004) Vitrectomy for chronic macular holes. Retina 24:341–347

    Article  PubMed  Google Scholar 

  46. Gupta B, Laidlaw DA, Williamson TH, Shah SP, Wong R, Wren S (2009) Predicting visual success in macular hole surgery. Br J Ophthalmol 93:1488–1491

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

There are no financial interests to declare or funding bodies for this research.

Author information

Authors and Affiliations

  1. St Thomas’ Hospital, Lambeth Palace Road, London, UK, SE1 7EH

    Tom H. Williamson & Edward Lee

Authors
  1. Tom H. Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Lee.

Additional information

The authors have full control of all primary data, and agree to allow Graefe's Archive for Clinical and Experimental Ophthalmology to review data upon request.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williamson, T.H., Lee, E. Idiopathic macular hole: analysis of visual outcomes and the use of indocyanine green or brilliant blue for internal limiting membrane peel. Graefes Arch Clin Exp Ophthalmol 252, 395–400 (2014). https://doi.org/10.1007/s00417-013-2477-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-013-2477-2

Keywords

Search

Navigation